Stock Traders Buy High Volume of Call Options on Omeros (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) saw some unusual options trading activity on Wednesday. Stock traders purchased 7,487 call options on the company. This represents an increase of approximately 54% compared to the typical daily volume of 4,876 call options.

Insider Activity

In related news, CAO David J. Borges sold 30,000 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 12.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Omeros

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming bought a new position in shares of Omeros during the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Omeros in the fourth quarter valued at approximately $33,000. Arax Advisory Partners grew its holdings in shares of Omeros by 56.4% in the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 1,894 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Omeros by 16.5% in the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,004 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its position in Omeros by 34.6% in the fourth quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 1,938 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Stock Performance

OMER stock opened at $12.08 on Thursday. The company has a market capitalization of $856.47 million, a P/E ratio of -24.16 and a beta of 2.53. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The business has a 50-day simple moving average of $11.40 and a two-hundred day simple moving average of $9.78.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 EPS for the quarter, topping the consensus estimate of ($0.55) by $3.69. As a group, sell-side analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

Omeros News Summary

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 beat and swing to profit — Omeros reported Q4 net income of $86.5M (EPS $3.14), beating expectations and reversing a year-ago loss; the strong quarter was detailed in the company press release. Business Wire: Omeros Reports Q4 & Year-End 2025 Results
• Positive Sentiment: Novo Nordisk-related windfall and launch optimism — Coverage cites a deal with Novo that boosted Q4 results and contributed to after-hours upside and investor enthusiasm around Omeros’ commercial prospects. MSN: Omeros rises as Novo deal boosts Q4 earnings
• Positive Sentiment: Operational guidance: YARTEMLEA expected to be self‑sustaining in 2026; company targets positive cash flow in 2027 — this reduces near‑term funding risk and supports a more durable commercial story. Seeking Alpha: YARTEMLEA guidance
• Neutral Sentiment: Earnings call / transcript available — investors can review management’s details on the Novo arrangement, commercialization cadence, and regulatory updates in the earnings call coverage. Yahoo Finance: Q4 2025 Earnings Call Summary
• Neutral Sentiment: Unusual options flow — traders bought roughly 7,487 OMER call options today (≈54% above typical call volume), indicating speculative or directional interest but not confirming long-term conviction.
• Negative Sentiment: Technical / profit‑taking alert — a recent note flagged OMER moving above its 200‑day moving average and posed the question of whether to sell, highlighting potential for short‑term volatility and that some gains may be priced in. AmericanBankingNews: Omeros passes above 200‑day MA — Should You Sell?

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, January 27th. Wall Street Zen downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, HC Wainwright increased their price target on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.